Previous close | 0.0200 |
Open | 0.0200 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 92.50 |
Expiry date | 2024-06-21 |
Day's range | 0.0200 - 0.0200 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Explore Gilead's latest financial performance and strategic directions, including updates on HIV, oncology, and liver disease segments.
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The biotech reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.